Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis

• Published in: Frontiers in oncology Vol. 12; p. 997030
• Main Authors: Liu, Haonan, Ma, Xiao, Sun, Chenyu, Wu, Meng, Xu, Zhiyuan, Zhou, Shuang, Yao, Nan, Liu, Suya, Qin, Xiaobing, Han, Zhengxiang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 07.12.2022
• Subjects: adjuvant chemotherapy; cervical cancer; chemoradiotherapy; concurrent; meta-analysis; Oncology; concurrent; meta-analysis; adjuvant chemotherapy; chemoradiotherapy; cervical cancer
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.997030

This study aimed to assess the efficacy and safety of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) in patients with locally advanced cervical cancer (LACC) meta-analysis. A systematic literature search of MEDLINE, PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials was conducted from January 10, 1966 to May 20, 2022. Randomized controlled trials and observational studies comparing the CCRT alone with CCRT plus ACT were included. The literature search, quality assessment, and data extraction were conducted by two reviewers independently. The primary endpoints were 3-year rates of overall survival (OS) and progression-free survival (PFS). Complete response rate, local recurrence, distant metastasis, and adverse events were secondary outcomes. The hazard ratios (HRs) and relative risk (RR) were pooled. Nine studies with a total of 2732 patients were included in this meta-analysis, including 1411 patients in the CCRT group and 1321 in the CCRT plus ACT group. The HR for 3-year rates of OS and PFS of the CCRT group compared with the CCRT plus ACT group was 0.72 [95%confidence interval (CI) = 0.44-1.17] and 0.78 (95%CI = 0.5-1.75), respectively. No significant differences were observed between the two groups in the complete response rate (RR = 1.06, 95%CI = 0.96-1.16). However, local recurrence and distant metastasis were significantly lower in the CCRT plus ACT group than in the CCRT group (RR = 0.63, 95%CI = 0.44 -0.91 and RR = 0.64, 95%CI = 0.47-0.88). Grade 3-4 acute toxicities were more frequent in the CCRT plus ACT group (RR = 1.73, 95%CI =1.19-2.52). Although associated with a decreased risk of local recurrence and distant metastasis, ACT did not significantly improve the survival rate and the complete response rate with increasing grade 3-4 acute toxicities in patients with LACC. Thus, this ACT regimen cannot be recommended for patients with LACC. https://inplasy.com/inplasy-2022-9-0089/, identifier INPLASY202290089.